Fibromyalgia
Conditions
Keywords
fibromyalgia, quetiapine, amitriptyline
Brief summary
Quetiapine, a second generation antipsychotic, has shown beneficial activity on fibromyalgia symptomatology, administered as add-on treatment, in a sample of 35 patients. The purpose of the present study is to compare, in a controlled setting, the efficacy and the tolerability of quetiapine extended release with amitriptyline in the treatment of patients with fibromyalgia
Interventions
DRUGamitriptyline
initial dose 10 mg/day, target dose: 25 mg/day, maximum dose: 75 mg/day, dosage form: tablets, duration: 16 weeks
DRUGquetiapine
initial dose: 50 mg/day, target dose: 100 mg/day, maximum dose: 300 mg/day, dosage form:extended release tablets , duration: 16 weeks
Sponsors
AstraZeneca
Hospital Clinico Universitario San Cecilio
Universidad de Granada
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female patients aged 18 70 years. 2. Meeting American College of Rheumatology criteria for primary fibromyalgia: widespread aching pain in all four quadrants of the body and axial skeleton and greater than or equal to 11 of 18 tender points under digital palpation examination. 3. A FIQ total score (0 100) of 40 or greater 4. A score of 4 or greater on the average pain item of the BPI 5. Written informed consent 6. Female patients of childbearing potential must be using a reliable contraceptive method and have a negative urine human chorionic gonadotropin (HCG) test at enrolment. 7. Able to understand and comply with the requirements of the study.
Exclusion criteria
1. Evidence of current traumatic injury, inflammatory rheumatic disease, or infectious or endocrine related joint disease. 2. A lifetime history of hypomania, mania, psychosis or dementia. 3. Current primary Axis I diagnosis other than major depressive disorder 4. Substance or alcohol dependence at enrolment and within the past 12 months (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM IV 5. Severe depression as evidenced by a Beck Depression Inventory score ≥ 30 6. Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others 7. History of seizures 8. Known lack of response to 2, or more than 2, different type of antidepressants in depression of fibromyalgia. 9. Pregnancy or breast feeding. 10. Patients with a history of urinary retention, angle closure glaucoma, or increased intraocular pressure. 11. Patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease or conditions which would predispose patients to severe hypotension (dehydration, hypovolemia and treatment with antihypertensive medications). 12. Patients who have received IMAOs, SSRIs or other antidepressants within two weeks of randomization. 13. Current or past history of kidney or liver insufficiency 14. Prior to randomization. Unwillingness to discontinue previously prescribed drugs for fibromyalgia other than those authorized in the protocol, as acetaminophen and bromazepam 15. Patients who have received quetiapine or amitriptyline within 1 year of randomization. 16. Patients with known intolerance or lack of response to quetiapine fumarate and/or amitriptyline, as judged by the investigator 17. Use of any of the following cytochrome P450 3A4 inhibitors within 14 days of enrolment, including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine, and saquinavir 18. Use of any of the following cytochrome P450 inducers within 14 days of enrolment, including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John's wort, and glucocorticoids 19. Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM IV criteria within 4 weeks of enrolment 20. Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment, with clinical relevance. 21. Unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension), as judged by the investigator 22. Involvement in planning and conduct of the study 23. Previous enrolments or randomisation of treatment in the present study. 24. Participation in another trial with drugs within 4 weeks of enrolment into this study or a longer period in accordance with local requirements. 25. Patients with uncontrolled Diabetes Mellitus (DM) 26. An absolute neutrophil count (ANC) equal or lower than 1.5 x 109 per liter. 27. Patients who show at the randomization visit a reduction in the FIQ total score equal or greater than 20% from the screening visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change from baseline to endpoint in the total score of Fibromyalgia Impact Questionnaire | baseline, 4, 8, 12 and 16 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline to endpoint in the scores of the Brief Pain Inventory, the Pittsburgh Sleep Quality Inventory, the Beck Depression Inventory, and the State and Trait Anxiety Inventory | baseline, 4, 8, 12 and 16 weeks |
| Discontinuation rates due to treatment-related adverse events, proportion of patients experiencing adverse events, proportion of patients experiencing serious adverse events, adverse events description and classification. | baseline, 0, 4, 8, 12 and 16 weeks |
Countries
Spain
Outcome results
None listed